FDA Approves Elranatamab for Multiple Myeloma : vimarsana.co

Elranatamab is an off-the-shelf, B-cell maturation antigen CD3-targeted bispecific antibody.

Related Keywords

, Pfizer , Drug Administration , Priority Review , Breakthrough Therapy Designation , Risk Evaluation , Mitigation Strategy , Multiple Myeloma , Myeloma , Plasma Cell Myeloma , Biologic Therapy , Antigens , Us Food And Drug Administration , Nited States Food And Drug Administration , Fda , Refractory , Toxicology , Cytokines , Monoclonal Antibody , Etuximab , Ituximab , Proteasome Inhibitor , Bortezomib , Risk Evaluation And Mitigation Strategies Rems , Neutropenia , Patient Safety , Practice Management ,